Cardiovascular disease remains a significant health challenge today. Thanks to advancements in science, innovation, and organized healthcare, we've made great strides in combating sudden cardiovascular events, saving numerous lives. However, factors like aging, lifestyle changes, and diabetes contribute to a rise in chronic heart conditions. By 2030, nearly 2 million people in the Netherlands—33% more than today—will be affected.

In response, the Dutch CardioVascular Alliance (DCVA) was formed. Bringing together twenty-four leading organisations, including patient representatives, researchers, healthcare providers, industry, and government, the DCVA aims to tackle this challenge alongside the nation's top scientists.

We’re close to reaching our goal. Advancements in technology, such as medical big data, high-resolution imaging, molecular diagnostics, biotechnology, high-throughput sequencing, home automation, sensors, and more, are creating opportunities for early detection and personalized prevention and intervention. We plan to allocate 1 billion euros by 2030.

We've built a solid foundation, but we see greater potential for impact in the Dutch cardiovascular community by forming consortia focused on health, social, and economic outcomes. To achieve our goals, the Dutch CardioVascular Alliance (DCVA) will invest in establishing an exceptional and enduring environment for cardiovascular innovations, with a focus on six key priorities.

The DCVA consists of the Partner Assembly and is supported by the supervisory board, management team and the chairs of the six pillars.